Open access
Sep 2026
Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience
In this two-center retrospective cohort, nivolumab was associated with longer PFS and OS than axitinib in the second-line treatment of mRCC, and these associations remained significant after adjustment for IMDC risk group and year of treatment initiation.
Irfan Bugday, İlknur Deliktaş Onur, M. Inanc et al.
· Journal of Clinical Medicine · 0 citations